Orlistat for the management of overweight individuals and obesity: a review of potential for the 60-mg, over-the-counter dosage (Q36904913)

17 August 2017

1 reference

title

Orlistat for the management of overweight individuals and obesity: a review of potential for the 60-mg, over-the-counter dosage (English)

1 reference

17 August 2017

0 references

James W Anderson

1

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

Expert Opinion on Pharmacotherapy

17 August 2017

published in

1 reference

17 August 2017

volume

8

1 reference

17 August 2017

issue

11

1 reference

17 August 2017

page(s)

1733-1742

1 reference

Prevalence of overweight and obesity in the United States, 1999-2004

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

The worldwide obesity epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Obesity as a cardiovascular risk factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Body mass index is the main risk factor for arterial hypertension in young subjects without major comorbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Obesity accelerates the progression of coronary atherosclerosis in young men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Importance of Weight Management in Type 2 Diabetes: Review with Meta-analysis of Clinical Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Systematic review: an evaluation of major commercial weight loss programs in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Weight loss with self-help compared with a structured commercial program: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Randomized trial of a multifaceted commercial weight loss program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Zonisamide for weight loss in obese adults: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Anorectics on trial: a half century of federal regulation of prescription appetite suppressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Availability of weight-loss supplements: Results of an audit of retail outlets in a southeastern city.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Short-term administration of orlistat reduced daytime triglyceridemia in obese women with the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Orlistat: a review of its use in the management of patients with obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Orlistat--a novel weight loss therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

36 year old man presenting with pancreatitis and a history of recent commencement of Orlistat case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Effects of Orlistat, a Lipase Inhibitor, on the Pharmacokinetics of Three Highly Lipophilic Drugs (Amiodarone, Fluoxetine, and Simvastatin) in Healthy Volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Clinical practice. Anorexia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Bulimia nervosa and misuse of orlistat: two case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Orlistat misuse in bulimia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Case report of abuse of Orlistat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Use of nonprescription weight loss products: results from a multistate survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Long-term weight loss and breakfast in subjects in the National Weight Control Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

The relationship of breakfast and cereal consumption to nutrient intake and body mass index: the National Heart, Lung, and Blood Institute Growth and Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

The effect of breakfast type on total daily energy intake and body mass index: results from the Third National Health and Nutrition Examination Survey (NHANES III).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Persons successful at long-term weight loss and maintenance continue to consume a low-energy, low-fat diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

Metabolic and weight loss effects of long-term dietary intervention in obese patients: four-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1733

10.1517/14656566.8.11.1733

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference